Contrary to expectation: Preserved renal function after using PD-1 Inhibitor Cemiplimab-rwlc in a kidney transplant recipient
<p>The use of immune checkpoint inhibitors in transplant recipients with malignancy is associated with the risk of graft failure due to acute rejection. There is limited literature regarding the use of Cemiplimab-rwlc (Libtayo) in kidney transplant patients. Here we present a case of using Cem...
সংরক্ষণ করুন:
| প্রধান লেখক: | , , |
|---|---|
| বিন্যাস: | গ্রন্থ |
| প্রকাশিত: |
Archives of Organ Transplantation - Peertechz Publications,
2022-09-08.
|
| বিষয়গুলি: | |
| অনলাইন ব্যবহার করুন: | Connect to this object online. |
| ট্যাগগুলো: |
ট্যাগ যুক্ত করুন
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!
|
| সংক্ষিপ্ত: | <p>The use of immune checkpoint inhibitors in transplant recipients with malignancy is associated with the risk of graft failure due to acute rejection. There is limited literature regarding the use of Cemiplimab-rwlc (Libtayo) in kidney transplant patients. Here we present a case of using Cemiplimab-rwlc (Libtayo), a Programmed Death receptor-1 (PD-1) blocking antibody for locally advanced and metastatic Cutaneous Squamous Cell Carcinoma (CSCC), in a kidney transplant recipient.</p><p><br></p> |
|---|---|
| ডিওআই: | 10.17352/2640-7973.000020 |